Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
SINGAPORE, Nov, 01 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
3F Mosquito, a fragrance made up of specialized oils sourced from botanicals that mosquitoes avoid, has shown 100% repellency against mosquitoes in laboratory testing. Global BioLife contracted U.S-based Snell Scientifics LLC ("Snell") in Meansville, Georgia to conduct the mosquito studies for the mosquito deterring technologies.
In August 2017 SeD announced that Global BioLife was collaborating with U.S-based Chemia Corporation to develop a suite of fragrances for medical applications referred to as 3F (Functional Fragrance Formulation). Global BioLife entered into further collaboration with Chemia to co-develop 3F Mosquito for laundry detergents, shampoos and lotions.
3F Mosquito products are based on extensive research of botanical oils which possess mosquito repelling properties. When 3F is infused into products such as detergents, shampoos, and lotions, consumers will be provided with multiple layers of protection against mosquito bites, a revolutionary alternative to traditional mosquito repellents.
"Chemia is very excited to introduce these sustainable and tested fragrances to provide natural alternatives to protecting consumers from the risk of mosquito transmitted diseases," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
The uniquely-designed mosquito deterring paints and functional fabric both deter mosquitoes by chemical-free photonic means; a wavelength of light is emitted that mosquitoes avoid. Snell reported that Global BioLife's photonic mosquito paints and mosquito fabric both exhibit degrees of repellency effective against mosquitoes.
Global BioLife and Chemia have designed the mosquito deterring fabric for use in outdoor apparel, hats, tents, and other camping gear. The mosquito deterring paints were designed as exterior paints for homes as well as commercial applications. These new mosquito deterring technologies are non-chemical methods of repelling mosquitoes for consumers.
Mr. Daryl Thompson, Global BioLife Director of Scientific Initiatives, said "The objective in the design of 3F Mosquito was to identify and create a suitable formula that was both pleasant and would excel in protective abilities against mosquitoes. These oils are scientifically proven to affect mosquitoes' receptors, essentially making the mosquito blind to your presence. 3F offers a pleasant scent while providing layers of protection to keep people safe from mosquito bites."
The market for safe mosquito repellents and deterrents is growing as the risk of Zika grows. The most vulnerable group of our population at highest risk for Zika infection may be pregnant women, because of their avoidance and dislike of products containing Deet. The US Center for Disease Control has released multiple statements that the use of Deet is safe, however pregnant women continue to be hesitant to use Deet-containing products.
Dr. Peggy Tang, Global BioLife's CEO, commented: "We expect that these new techniques for fighting mosquito bites will be very appealing to consumers. We are providing unique and useful products, free of harsh chemicals. Due to the perceived toxicity of Deet and the avoidance of chemicals by consumers, Global BioLife's chemical-free products will have a direct advantage over traditional mosquito repellents."
"Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This collaboration marks one of the first steps in actively changing the game of healthcare," said SeD and Global BioLife Executive Chairman Mr. Chan Heng Fai.
Mr. Thomas Meyer added: "This groundbreaking partnership with Global BioLife sets the stage for a steady stream of innovative fragrances that feature functional properties in various consumer product applications."
In addition to 3F Mosquito, Global BioLife is working with Chemia on the formulation of additional 3F fragrances to fight stress and anxiety and 3F for anti-viral medical applications.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") and Australian Exchange-listed Holista CollTech Limited ("Holista") in equal proportions of 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com
About Chemia Corporation
Chemia Fragrance and Flavor provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. For more information, please visit: http://www.chemiacorp.com.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email [email protected].
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
DOCOMO and Kyoto University Develop World's First AI System to Detect Bridge Deterioration using Video-based Vehicle Weights and Structural Deflection
Dec 05, 2019 14:17 JST
Fujitsu Successfully Grows Diamond Film to Boost Heat Dissipation Efficiency of GaN HEMT
Dec 05, 2019 13:06 JST
KMD buys IT System for Disaster Assistance from Plass Data
Dec 05, 2019 12:31 JST
Fujitsu Takes Key Step Toward Implementing SAP S/4HANA Manufacturing for Production Engineering and Operations to Streamline Aircraft Production at Kawasaki Heavy Industries
Dec 05, 2019 11:11 JST
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Dec 05, 2019 09:11 JST
Mitsubishi Corporation: Dedicated Biomass Power Generation at Suzukawa Energy Center
Dec 04, 2019 16:35 JST
Panasonic and Toyota Confirm Location and Executive Structure of Town Development Joint Venture
Dec 04, 2019 15:32 JST
Mitsubishi Corporation Establishes New Tech Subsidiary, MC Digital
Dec 03, 2019 16:49 JST
MHI Thermal Systems Wins 22nd "Environment Minister's Award for Global Warming Prevention Activity" for its High-efficiency Next-generation ETI-Z Series Centrifugal Chillers
Dec 03, 2019 15:08 JST
Hitachi: Power Grid Protection System Starts its Demonstration Operation in Poland
Dec 03, 2019 12:31 JST
MHPS to Exhibit at the Japan Pavilion at COP25 in Madrid, Spain from December 2
Dec 02, 2019 16:32 JST
Fujitsu Begins Shipping Supercomputer Fugaku
Dec 02, 2019 13:23 JST
Mitsubishi Heavy Industries Asia Pacific Establishes Yangon Representative Office
Dec 02, 2019 12:57 JST
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019 09:23 JST
Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China
Dec 02, 2019 09:08 JST
Showa Denko Announces Changes in Representative Director and Other Members of Management
Nov 29, 2019 16:00 JST
Fujitsu Laboratories and Aichi Cancer Center in Japan Sign Comprehensive Joint Research Agreement to Drive Advances in Cancer Genomic Medicine with AI Technology
Nov 29, 2019 11:17 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Cargo-Passenger Ship for Tokai Kisen
Nov 28, 2019 13:30 JST
Mazda Production and Sales Results for October 2019
Nov 28, 2019 12:25 JST
Ogier, Evans and Rovanpera: An Exciting New Line-Up to Drive the Toyota Yaris WRC in 2020
Nov 28, 2019 08:51 JST